We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Safety and Efficacy of Using LEORTEC-300 System For Hair Removal Treatment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00348257
Recruitment Status : Completed
First Posted : July 4, 2006
Last Update Posted : February 28, 2007
Information provided by:
Leortec Medical Systems Ltd

Brief Summary:

Removal of unwanted hair is one of the most commonly sought cosmetic solutions. Traditional methods, such as shaving, depilatories, tweezing and waxing result in only temporary hair removal, and thus require extensive maintenance. Long term hair removal via electrolysis is generally unsatisfactory due to its time consuming, painful nature and the associated risk of scarring or pigmentary changes. Moreover, the efficacy of electrolysis is user dependent and is estimated to be reduction of only 15-50% of the unwanted hair3.

The more modern approach to long term hair removal involves laser and Intense Pulsed Light (IPL) treatment modalities. These technologies are based on the scientific principle of selective photothermolysis. During the treatment, the light energy is absorbed by the hair’s pigment (melanin) and transmitted through the hair shaft to the follicle. Conversion of this energy into heat causes a rise in the hair temperature, leading to destruction of the follicle and disruption of the hair growth mechanism, while leaving the skin undamaged.

Both laser and light devices have been proven successful in inducing permanent hair removal, as well as delayed hair growth, while causing minimal discomfort and complications. The light devices are based on the IPL technology, which differs from laser light in various physical aspects. The main difference is that while lasers emit light at a distinct wavelength, IPL delivers a wide range of wavelengths (400 1400 nm), thus allowing greater flexibility in aspects of body area, hair color and skin type LEORTEC LTD. has developed an innovative device that integrates the two treatment modalities: Laser and Intense Pulse Light (IPL) and in addition MLS - Multi Light Source- a combination of the two modalities. The purpose of this study is to evaluate the safety and efficacy of using Leortec 300 device for hair removal treatment.

Condition or disease Intervention/treatment Phase
Epilation Device: Hair removal by laser/IPL device Phase 1 Phase 2

Detailed Description:


  1. Primary Objective

    • Safety

      • To evaluate the safety of using LEORTEC-300 System for hair removal treatment, in different skin/hair colors and anatomical sites.
  2. Secondary Objectives

    • Effectiveness

      • To assess the effectiveness of using the LEORTEC-300 system for hair removal treatment in different skin/hair colors and anatomical sites.
      • Patient Satisfaction Immediately after the treatment patients will be asked to rate pain level which they felt during the treatment.
      • Physician’s Satisfaction Physician's satisfaction from the technique, equipment and hair removal will be assessed by physician’s questionnaire.


This is a two-sites, prospective, controlled study to further test the safety and effectiveness of the LEORTEC-300 system in hair removal treatment.


1.Source and Number Subjects for the study will be recruited from patients within the community who have sought treatment for hair removal from the investigative physicians and meet all of the eligibility criteria listed below. There will be a total of 30 patients.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Safety and Efficacy of Using LEORTEC-300 System For Hair Removal Treatment
Study Start Date : July 2006
Estimated Study Completion Date : September 2006

Primary Outcome Measures :
  1. Hair removal efficiency 1- N1/N2 (N1 - Average number of hairs after the treatment
  2. N2 - Average number of hairs before the treatment)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy males/females between the ages of 18 to 70
  • Subject is willing to go trough hair removal treatment.
  • Subject understands the study procedure.
  • Subject is willing to sign the inform consent.
  • Subject must have the ability to comply with the study procedures and follow- up.

Exclusion Criteria:

  • Age < 18 years or > 70 years.
  • Use of medication for which 400nm to 1400nm light exposure is contraindicated
  • Coagulation disorder.
  • Infection / abscess / pains in treatment target area.
  • Recently tanned skin.
  • Photosensitivity or allergy.
  • Psoriasis.
  • Skin cancer.
  • Diabetes.
  • Pregnancy.
  • Tattoo on targeted area.
  • History of keloid scarring.
  • Use of aspirin or antioxidants
  • Eczema or dermatitis.
  • Subject is suffering extreme general weakness.
  • Subject objects to the study protocol.
  • Physician objection.
  • Known cognitive or psychiatric disorder
  • Participation in any other clinical trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00348257

Elisha Hospital
Haifa, Israel, 34636
Sponsors and Collaborators
Leortec Medical Systems Ltd
Study Director: Hanna Levy, PhD Leortec Medical Systems

ClinicalTrials.gov Identifier: NCT00348257     History of Changes
Other Study ID Numbers: LEORTC-HR-001
First Posted: July 4, 2006    Key Record Dates
Last Update Posted: February 28, 2007
Last Verified: February 2007